Deferasirox + Deferoxamine (DFO)
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Transfusion-dependent β-thalassemia Patients
Conditions
Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload
Trial Timeline
Jan 1, 2011 → Jun 1, 2014
NCT ID
NCT01459718About Deferasirox + Deferoxamine (DFO)
Deferasirox + Deferoxamine (DFO) is a phase 2 stage product being developed by Novartis for Transfusion-dependent β-thalassemia Patients. The current trial status is terminated. This product is registered under clinical trial identifier NCT01459718. Target conditions include Transfusion-dependent β-thalassemia Patients, Cardiac Iron Overload.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01459718 | Phase 2 | Terminated |
Competing Products
8 competing products in Transfusion-dependent β-thalassemia Patients
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Deferasirox | Novartis | Phase 3 | 77 |
| Deferasirox dispersable tablet (DT) + Deferasirox film coated tablet (FCT) | Novartis | Phase 2 | 52 |
| Deferasirox granule formulation + Deferasirox DT formulation | Novartis | Phase 2 | 52 |
| Deferoxamine + Deferasirox | Novartis | Approved | 85 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo Matching Mitapivat + Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| SLN124 + Placebo | Silence Therapeutics | Phase 1 | 25 |
| SLN124 is a GalNAc conjugated double stranded fully modified siRNA. Sodium chloride 0.9% w/v is used as Placebo | Silence Therapeutics | Phase 1 | 25 |